EIN Presswire
Pharmaceutical advertising is doing more than raising awareness—it’s prompting action, according to a new survey from Swoop, the AI-driven, privacy-compliant healthcare marketing platform. The findings, set to be unveiled at Fierce Pharma Week 2025 in Philadelphia, suggest that treatment ads are significantly influencing patients with chronic conditions.
Swoop surveyed 902 members of the MyHealthTeam community between March and July 2025. Results show that 97% had seen treatment ads, 83% found them beneficial, and 67% took some form of action after seeing an ad, with 53% taking steps directly related to treatment.
“Treatment ads are influencing patient perceptions and driving meaningful actions in their healthcare journey,” said Eric Peacock, Co-founder of MyHealthTeam and Swoop Chief Patient Officer. He notes that informed patients can better navigate their chronic condition journeys and engage in smarter conversations with doctors.
The findings come as pharma companies ramp up advertising spend. TV ad investment reached $2.18 billion in the first half of 2025, while digital healthcare and pharma ad spend is projected to hit $24.71 billion by 2026, emphasizing the industry’s shift toward multi-channel patient engagement. Swoop’s survey validates that these investments are paying off in tangible patient actions.
At Fierce Pharma Week, Swoop will detail the full survey results during the panel “From Awareness to Action: How Pharma Advertising Impacts the Chronic Condition Journey”, featuring experts from Novo Nordisk, Wavemaker, and a patient advocate. Attendees can also visit Swoop Booth #1009 for hands-on insights and strategies for patient-focused campaigns.
Swoop’s privacy-safe, data-driven marketing platform aims to transform healthcare outreach by connecting patients, providers, and brands. Its solutions help pharma marketers not just reach audiences at scale but drive better patient outcomes through actionable intelligence—putting the patient at the center of omnichannel campaigns.
BusinessWire
